Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19). The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins are reported.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065233 | PMC |
| http://dx.doi.org/10.1016/j.ijid.2021.04.068 | DOI Listing |
Publication Analysis
Top Keywords
prolonged severe
8
severe sars-cov-2
4
sars-cov-2 infection
4
infection patients
4
patients b-cell-depleting
4
b-cell-depleting drug
4
drug treated
4
treated tailored
4
tailored approach
4
approach prolonged
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!